Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kaleido Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/01/2021 | 06:36am EST

Kaleido Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 23.09 million compared to USD 23.13 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.65 a year ago. For the nine months, net loss was USD 70.02 million compared to USD 61.6 million a year ago. Basic loss per share from continuing operations was USD 1.68 compared to USD 1.89 a year ago.


ę S&P Capital IQ 2021
All news about KALEIDO BIOSCIENCES, INC.
01/21Kaleido Reports Findings From Study Data of Proposed Inflammatory Bowel Disease Treatme..
MT
01/21Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 ..
GL
01/21Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 ..
GL
2021KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from NASDAQ Biotechnology Index
CI
2021Kaleido Biosciences Expands and Extends Collaboration With Janssen
MT
2021Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potent..
GL
2021Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potent..
CI
2021Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ..
GL
2021Chardan Adjusts Price Target on Kaleido Biosciences to $11 From $15 on Pipeline Assets ..
MT
2021Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
GL
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 1,61 M - -
Net income 2021 -94,6 M - -
Net cash 2021 5,83 M - -
P/E ratio 2021 -0,93x
Yield 2021 -
Capitalization 89,4 M 89,4 M -
EV / Sales 2021 52,1x
EV / Sales 2022 48,8x
Nbr of Employees 82
Free-Float -
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 2,10 $
Average target price 14,80 $
Spread / Average Target 605%
EPS Revisions
Managers and Directors
Daniel L. Menichella President, Chief Executive Officer & Director
William E. Duke Chief Financial Officer
Theo Melas-Kyriazi Chairman
Johan van Hylckama Vlieg Chief Scientific Officer
Kimberly Hocknell Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-12.13%89
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508